Combined treatment with methotrexate and ursodeoxycholic acid in non-cirrhotic primary biliary cirrhosis

Acta Clinica Belgica

Volumn 51, Issue 1, 1996, Pages 8-18

  Van Steenbergen, W ^a   Sciot, R ^a   Van Eyken, P ^a   Desmet, V ^a   Fevery, J ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; URSODEOXYCHOLIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INTERSTITIAL PNEUMONIA; MALE; ORAL DRUG ADMINISTRATION; PRIMARY BILIARY CIRRHOSIS; THROMBOCYTOPENIA;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; CHOLAGOGUES AND CHOLERETICS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER CIRRHOSIS, BILIARY; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; URSODEOXYCHOLIC ACID;

EID: 0029878176     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Sherlock S. Primary biliary cirrhosis and vanishing bile ducts. In: McIntyre N. Benhamou J-P, Bircher J, Rizetto M, and Rodes J. Eds. Oxford textbook of clinical hepatology. Volume 2. Oxford: Oxford University Press. 1991; 743-50.
2. Kaplan MM. Primary biliary cirrhosis. In: Schiff L, Schiff ER, Eds. Diseases of the liver. Volume I. 7th ed. (Philadelphia: Lippincott Company, 1993; 377-410.
3. Wiesner RH, Grambsch PM, Lindor KD, Ludwig J. Dickson ER. Clinical and statistical analyses of new and evolving therapies for primary biliary cirrhosis. Hepatology. 1988; 8: 668-76.
4. Kaplan MM, Arora S, Pincus SH. Primary sclerosing cholangius and low-dose oral pulse methotrexate therapy. Clinical and histologic response. Ann Intern Med. 1987; 106: 231-45.
5. Kaplan MM, Knox TA. Treatment of primary biliary cirrhosis with low-dose weekly methotrexate. Gastroenterology. 1991; 101: 1332-38.
6. Bergasa NV, Hoofnagle JH, Axiotis CA, Rabin L, Park Y, Jones EA. Oral methotrexaic (MTX) for primary biliary cirrhosis (PBC): preliminary report. Gastroenterology. 1991; 100: A720.
7. Buscher H-P, Zietzschmann Y, Gerok W, Positive responses to methotrexate and ursodeoxycholic acid in patients with primary biliary cirrhosis responding insufficiently 10 ursodeoxycholic acid alone. J Hepatol 1993; 18: 9-14.
8. Van Steenbergen W, Sciot R, Desmet V, Fevery J. One year treatment with methotrexate (MTX) in patients with primary biliary cirrhosis (PBC). J Hepatol. 1992; 16: S41.
9. Poupon R, Chrétien Y, Poupon RE, Ballet F. Calmus Y, Darnis F. Is Ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet. 1987; I: 834-6.
10. Poupon RE, Balkau B, Eschwège E, Poupon R. and the UDCA-PBC study group. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 1991; 324: 1548-54.
11. Heathcote EJL, Cauch-Dudek K. Walker et al. The Canadian Multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 1994; 19: 1149-56.
12. Lindor KD, Dickson ER, Baldus WP et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994; 106: 1284-90.
13. Leuschner U, Fischer H, Kurtz W et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology. 1989; 97: 1268-74.
14. Matsuzaki Y, Tanaka N, Osuga T et al. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis. Am J Gastroenterol. 1990; 85: 15-23.
15. Poupon RE, Chrétien Y, Balkau B, Niard AM, Poupon R and the UDCA-PBC study group. Ursodeoxycholic therapy for primary biliary cirrhosis: a four year controlled study. Hepatology. 1992; 16: 91A.
16. Hadziyannis SJ, Hadziyannis ES, Lianidou E, Makris A. Long-term treatment of primary biliary cirrhosis with ursodeoxycholic acid: the third year of a controlled trial. In: Paumgartner G, Stiehl A, Gerok W, Eds. Bile acids as therapeutic agents. From basic science to clinical practice. Dordrecht: Kluwer Academic Publishers, 1990; 287-96.
17. Perdigoto R, Wiesner RH. Progression of primary biliary cirrhosis with ursodeoxycholic acid therapy. Gastroenterology. 1992; 102: 1389-91.
18. Kaplan MM. New strategies needed for treatment of primary biliary cirrhosis. Gastroenterology. 1993; 104: 651-3.
19. Van de Meeberg PC, van Erpecum KJ, van Berge- Henegouwen GP. Therapy with ursodeoxycholic acid in cholestatic liver disease. Scand J Gastroenterol. 1993; 28 Suppl 200: 15-20.
20. Kaplan MM. The therapeutic effects of ursodiol and methotrexate are additive and well tolerated in primary biliary cirrhosis (PBC). Hepatology. 1992; 16: 92A.
21. Flowers MA, Heathcote J, Wanless IR et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med. 1990; 112: 381-2.
22. Petrie A. Why randomization is essential and how to do it. In: Tygstrup N, Lachin JM, Juhl E, Eds. The randomized clinical trial and therapeutic decisions. New York: Marcel Dekker Inc. 1982; 105-16.
23. Podda M, Ghezzi C, Battezzati PM et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci. 1989; 34: 59S-65S.
24. Parmentier GG, Janssen GA, Eggermont EA, Eyssen HJ. C27 bile acids in infants with coprostanic acidemia and occurrence of a 3α,7α, 12α-trihydroxy-5β-C29 dicarboxylic bile acid as a major component in their serum. Eur J Biochem. 1979; 102: 173-83.
25. Klein R, Klöppel G, Garbe W, Fintelmann V, Berg PA. Antimitochondrial antibody profiles determined at early stages of primary biliary cirrhosis differentiate between a benign and a progressive course of the disease. A retrospective analysis of 76 patients over 6-18 years. J Hepatol. 1991; 12: 21-7.
26. Klein R, Huizenga JR, Gips CH, Berg PA. Antimitochondrial antibody profiles in patients with primary biliary cirrhosis bcfore orthotopic liver transplantation and titres of antimitochondrial antibody-subtypes after transplantation. J Hepatol. 1994; 20: 181-9.
27. Wiesner RH, Ludwig J, Lindor KD et al. A controlled trial of cyclosporine in the treatment of primary biliary cirrhosis. N Engl J Med. 1990; 322: 1419-24.
28. Dickson ER, Grambsch PM, Fleming TR, Fisher LD, Langworthy A. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology. 1989; 10: 1-7.
29. Ludwig J, Dickson ER, McDonald GSA. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Path Anat. 1978; 379: 103-12.
30. Weber P, Scheurlen M, Wiedmann K-H. Methotrexat in der Therapie der primären biliären Zirrhose. Dtsch Med Wschr. 1991; 116: 1347-52.
31. Rosenthal GJ, Germolec DR, Lamm KR, Ackermann MF, Luster MI. Comparative effects on the immune system of methotrexate and trimetrexate. Int J Immunopharmacol. 1987; 9: 793-801.
32. Miller LC, Dinarello CA. Methotrexale inhibits interleukin-1 activity. Arthritis Rheum. 1986; 29: S86.
33. Miller LC, Cohell SE, Orencole SF, Dinarello CA. Interleukin 1B is structurally related to dihydrofolate reductase: effect of methotrexate on IL-1. Lymphokine Res. 1988; 7: 272A.
34. Asako H. Wolf RE, Granger DN. Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate. Gastroenterology. 1993; 104: 31-7.
35. Kaplan MM, Knox TA. Effective treatment of precirrhotic primary biliary cirrhosis (PBC) with methotrexate (MTX): remission in some. Hepatology. 1989; 10: 585.
36. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histologic features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med. 1983; 308: 1-7.
37. Christensen E, Neuberger J, Crowe J et al. Beneficial effect of azathioprine and prediction of prognosis in primary biliary cirrhosis. Final results of an international trial. Gastroenterology. 1985; 89: 1084-91.
38. Gilbert SC, Klintmalm G, Menter A, Silverman A. Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis: a word of caution in light of the expanding use of this "steroid-sparing" agent. Arch Intern Med. 1990; 150: 889-91.
39. Zachariae H, Sogaard H. Methotrexate-induced liver cirrhosis: a follow-up. Dermatologica. 1987; 175: 178-82.
40. Walker AM, Funch D, Dreyer NA et al.Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis Rheum. 1993; 36: 329-35.
41. Lanse SB, Arnold GL, Gowans JDC, Kaplan MM. Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio. Dig Dis Sci. 1985; 30: 104-9.
42. Lewis JH, Schiff E. Methotrexate-induced chronic liver injury: guidelines for detection and prevention. Am J Gastroenterol. 1988; 88: 1337-45.
43. Searles G. McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol. 1987; 14: 1164-71.
44. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology. 1994; 107: 266-70.
45. Shiroky JB, Frost A, Skelton JD, Haegert DG, Newkirk MM, Neville C. Complications of immunosuppression associated with weekly low dose methotrexate. J Rheumatol. 1991; 18: 1172-75.
46. Ellman MH, Hurwitz H, Thomas C, Kozloff M. Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate. J Rheumatol. 1991; 18: 1741-43.
47. Zimmer-Galler I, Lie JT. Choroidal infiltrates as the initial manifestation of lymphoma in rheumatoid arthritis after treatment with low-dose methotrexate. Mayo Clin Proc. 1994; 69: 258-61.
48. Lindor KD, Dickson ER, Jorgensen RA et al. The combination of ursodeoxycholic acid and methotrexate for patients with primary biliary cirrhosis: the results of a pilot study. Hepatology. 1995; 22: 1158-62.